Dr. Federico V. Pallardó Calatayud
Principal Investigator
Research Group on Cellular and Organic Physiopathology of Oxidative Stress
Presentation
Dr. Pallardó studied Medicine at the Faculty of Medicine of the University of Valencia where he graduated in 1985 with the qualification of outstanding where he also obtained his doctorate “cum laude”.
After passing through the universities of Oxford in the United Kingdom and Harvard Medical School in the United States, where he obtained the prestigious NATO fellowship, he returned to Spain in 1992. He is currently a University Professor, being Dean of the Faculty of Medicine and Dentistry from the University of Valencia between 2011 and 2017. He has been a visiting professor at the Chicago Medical School.
He has been director of the Central Research Unit, coordinating the INCLIVA basic research laboratories for more than ten years. He has been the head of the CIBER group in its rare diseases division since 2007.
His research focuses on the role of oxidative stress in the pathophysiology of rare diseases and epigenetic regulation. He has more than 230 scientific publications, is a regular contributor to prestigious international journals and has directed 23 doctoral theses. Its h-index is currently 57 with more than 11,000 accumulated citations. He is a founding partner of the biotechnological company EPIDISEASE S.L. spin-off of the University of Valencia, CIBERER and INCLIVA. It holds four international patents. He directs the CIBERER-Biobank of the ISCIII.
He has been secretary of the SFRR (Europe) and has received various national and international awards such as the Fundación Salud 2000 Award for his research into rare diseases or the international project Saving lives at Birth from the Bill and Melinda Gates Foundation. He has been awarded the “SFRR-Europe Annual Award Lecture” by the Society for Free Radical Research in its 2020 edition.
He has been an advisory member of the Valencian Foundation for Advanced Studies and Jury of the Jaime I research awards on several occasions. He is an evaluator of research projects for national organizations from different countries in Europe and Latin America. He belongs to the editorial committee of several journals and is editor of “Redox Biology”
Publications
miRNAs Related to Immune Checkpoint Inhibitor Response: a systematic review. García-Giménez J, Saadi W, Ortega A, Lahoz A, Suay G, Carretero J, Pereda J, Fatmi A, Pallardó F, Mena-Molla S. International Journal of Molecular Sciences. 2024 Feb 1;25(3):1737. doi: 10.3390/ijms25031737. PMID: 38339019
Oxidative stress and metabolism meet epigenetic modulation in physical exercise. Garcia-Gimenez J, Canovas-Cervera I, Pallardo F. Free Radical Biology & Medicine. 2024 Jan 8:213:123-137. doi: 10.1016/j.freeradbiomed.2024.01.008. PMID: 38199289
Exacerbated response to oxidative stress in the Retinitis Pigmentosa CerklKD/KO mouse model triggers retinal degeneration pathways upon acute light stress. García-Arroyo R, Domènech E, Herrera-Ubeda C, Asensi M, de Arenas C, Cuezva J, Garcia-Fernàndez J, Pallardó F, Mirra S, Marfany G. Redox Biology. 2023 Oct:66:102862. doi: 10.1016/j.redox.2023.102862. PMID: 37660443
Extracellular histones trigger oxidative stress-dependent induction of the NF-kB/CAM pathway via TLR4 in endothelial cells. Perez-Cremades D, Bueno-Beti C, Garcia-Gimenez J, Ibanez-Cabellos J, Pallardo F, Hermenegildo C, Novella S. Journal of Physiology and Biochemistry. 2023 May;79(2):251-260. doi: 10.1007/s13105-022-00935-z. PMID: 36464762
Oxidative stress and epigenetics: miRNA involvement in rare autoimmune diseases. Ibanez-Cabellos J, Pallardo F, Garcia-Gimenez J, Seco-Cervera M. Antioxidants. 2023 Mar 25;12(4):800. doi: 10.3390/antiox12040800. PMID: 37107175
Persistent pulmonary fibrotic sequelae in patients with telomere shortening one year after severe COVID-19. Mulet A, González-Cabo P, Pallardó FV, Signes-Costa J. Archivos de Bronconeumologia. 2023 Nov 10:S0300-2896(23)00365-4. doi: 10.1016/j.arbres.2023.11.003. PMID: 37985282
CIBERER: Spanish national network for research on rare diseases: a highly productive collaborative initiative. Luque J, Mendes I, Gomez B, Morte B, de Heredia M, Herreras E, Corrochano V, Bueren J, Gallano P, Artuch R, Fillat C, Perez-Jurado L, Montoliu L, Carracedo A, Millan J, Webb S, Palau F, Lapunzina P, Pallardo Calatayud F, CIBERER Network. Clinical Genetics. 2022 May;101(5-6):481-493. doi: 10.1111/cge.14113. PMID: 35060122
Clinical and immunological aspects of microRNAs in neonatal sepsis. Fatmi A, Chabni N, Cernada M, Vento M, Gonzalez-Lopez M, Aribi M, Pallardo FV, Garcia-Gimenez JL. Biomedicine & Pharmacotherapy. 2021 Nov 19;145:112444. doi: 10.1016/j.biopha.2021.112444. PMID: 34808550
Extracellular histones activate endothelial NLRP3 inflammasome and are associated with a severe sepsis phenotype. Beltrán-García J, Osca-Verdegal R, Pérez-Cremades D, Novella S, Hermenegildo C, Pallardó FV, García-Giménez JL. Journal of Inflammation Research. 2022 Jul 25;15:4217-4238. doi: 10.2147/JIR.S363693. PMID: 35915852
Frataxin deficit leads to reduced dynamics of growth cones in dorsal root ganglia neurons of Friedreich’s Ataxia YG8sR model: a multilinear algebra approach. Munoz Lasso D, Molla B, Saenz Gamboa J, Insuasty E, de la Iglesia Vaya M, Pook M, Pallardo F, Palau F, Gonzalez-Cabo P. Frontiers in Molecular Neuroscience. 2022 Jun 13;15:912780. doi: 10.3389/fnmol.2022.912780. PMID: 35769335
Comparative analysis of chromatin-delivered biomarkers in the monitoring of sepsis and septic shock: a pilot study. Beltran-Garcia J, Manclus J, Garcia-Lopez E, Carbonell N, Ferreres J, Rodriguez-Gimillo M, Garces C, Pallardo F, Garcia-Gimenez J, Montoya A, Roma-Mateo C. International Journal of Molecular Sciences. 2021 Sep 14;22(18):9935. doi: 10.3390/ijms22189935. PMID: 34576097
DNA Methylation Analysis to Unravel Altered Genetic Pathways Underlying Early Onset and Late Onset Neonatal Sepsis. A Pilot Study. Lorente-Pozo S, Navarrete P, Garzón MJ, Lara-Cantón I, Beltrán-García J, Osca-Verdegal R, Mena-Mollá S, García-López E, Vento M, Pallardó FV, García-Giménez JL. Frontiers in Immunology. 2021 Feb 15;12:622599. doi: 10.3389/fimmu.2021.622599. PMID: 33659006
Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies. Pallardo Calatayud F, Pagano G, Rodriguez Melguizo L, González Cabo P, Lyakhovich A, Trifuoggi M. Translational Research. 2021 Mar;229:135-141. doi: 10.1016/j.trsl.2020.08.009. PMID: 32841735
IGF-1 haploinsufficiency causes age-related chronic cochlear inflammation and increases noise-induced hearing loss. Celaya A, Rodriguez-De la Rosa L, Bermudez-Munoz J, Zubeldia J, Roma-Mateo C, Avendano C, Pallardo F, Varela-Nieto I. Cells. 2021 Jul 3;10(7):1686. doi: 10.3390/cells10071686. PMID: 34359856
Projects
Title: Reposicionamiento de fármacos como tratamiento para la enfermedad de Huntington y la ataxia espinocerebelosa de tipo 3. Estudios en cultivos primarios de pacientes y en modelos animales transgénicos.
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico V. Pallardó Calatayud, Juan Antonio Navarro Langa
Duration: 2023 – 2025
Total budget: 147.620,00 €
Title: Sistema de espectrometría de masas acoplado a un sistema de cromatografía líquida de alta precisión
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2022 – 2022
Total budget: 300.000 €
Title: Test basados en péptidos spike-in y espectrometría de masas para la cuantificación de histonas circulantes y proteína APC, para el manejo clínico del paciente crítico
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Jose Luis García Giménez
Duration: 2022 – 2023
Total budget: 122.100 €
Title: Efecto de la infección por COVID-19 sobre la longitud del telómero y parámetros de función mitocondrial y su relación con la evolución a fibrosis pulmonar de tipo idiopático
Funding body: Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2021 – 2022
Total budget: 62.280 €
Title: NATAX: Nanozimas como aproximación terapéutica para el tratamiento del estrés oxidativo en la ataxia de Friedreich
Funding body: Universidad de Valencia – INCLIVA
Principal Investigator: José Vicente Ros Lis, Federico V. Pallardó Calatayud
Duration: 2021 – 2022
Total budget: 4.750 €
Title: Therapeutical strategies for cystinuria
Funding body: Marató TV3
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2021 – 2023
Total budget: 35.580 €
Title: Nuevas terapias en ataxia de Friedreich
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2020 – 2022
Total budget: 93.170 €
Title: Kit multiplex para la detección simultánea de biomarcadores de diagnóstico y pronóstico de sepsis y shock séptico por espectrometría de masas
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2018 – 2020
Total budget: 78.210 €
Title: From genes to therapy in neurodegenerative and neuromuscular disorders
Funding body: Conselleria de Educación, Investigación, Cultura y Deporte
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2018 – 2021
Total budget: 310.506 €
Title: Respuestas epigenéticas a cambios en el entorno redox nuclear. Posibles dianas terapéuticas en enfermedades raras
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2017 – 2019
Total budget: 105.875 €
Title: CIBER de Enfermedades Raras (CIBERer)
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2007 –
Total budget:
+ Info
Doctoral candidate: Garcés Díaz, Concepción
Director(s): Pallardó Calatayud, Federico; Romá Mateo, Carlos
Date of the defense: 19/12/2023
University: University de Valencia
Title: Identificación de los mecanismos epigenéticos relacionados con los fenómenos de inmunosupresión en sepsis y su uso como biomarcadores de pronóstico
Doctoral candidate: Osca Verdegal, Rebeca
Director(s):
Date of the defense: 19/05/2023
University: University de Valencia
Title: Papel de las membranas asociadas a retículo endoplasmático y mitocondria (MAMS) en la fisiopatología celular de la ataxia de Friedrich y su relevancia como diana terapéutica
Doctoral candidate: Robles Rodríguez, Laura
Director(s): Pallardo Calatayud, Federico; González Cabo, María Pilar
Date of the defense: 20/01/2023
University: Universitat de València
Title: Uso de las histonas circulantes y sus modificaciones post-traduccionales como biomarcadores en sepsis y shock séptico
Doctoral candidate: Beltrán García, Jesús
Director(s): García Giménez, José Luis; Pallardó Calatayud, Federico
Date of the defense: 20/01/2022
University: Universitat de València
Title: Proteínas nucleares y otros mediadores de inflamación en pacientes en shock séptico sometidos a terapias de remplazo renal
Doctoral candidate: Crespo Gomez, Mónica
Director(s): Cervera Montes, Manuel; Pallardó Calatayud, Federico; Romá Mateo, Carlos
Date of the defense: 25/06/2021
University: Universitat de València